Cue Biopharma (CUE)

NASDAQ
3.37
+0.06(+1.81%)
After Hours
3.35
-0.02(-0.59%)
- Real-time Data
  • Volume:
    182,156
  • Day's Range:
    3.31 - 3.44
  • 52 wk Range:
    2.36 - 18.42

CUE Overview

Prev. Close
3.31
Day's Range
3.31-3.44
Revenue
11.68M
Open
3.31
52 wk Range
2.36-18.42
EPS
-1.49
Volume
182,156
Market Cap
119.24M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
368,434
P/E Ratio
-2.23
Beta
1.72
1-Year Change
-69.67%
Shares Outstanding
35,381,743
Next Earnings Date
Nov 16, 2022
What is your sentiment on Cue Biopharma?
or
Market is currently closed. Voting is open during market hours.

Cue Biopharma News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Cue Biopharma Analysis

Cue Biopharma Company Profile

Cue Biopharma Company Profile

Employees
58

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralBuyBuySell
Technical IndicatorsSellStrong SellStrong BuyStrong BuyStrong Sell
SummaryNeutralSellStrong BuyStrong BuyStrong Sell
  • this expletive company... years and years of promoses. still nothing
    0